Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

Krzysztof W. Pankiewicz, Steven E. Patterson, Paul L. Black, Hiremagalur N. Jayaram, Dipesh Risal, Barry M. Goldstein, Lieven J. Stuyver, Raymond F. Schinazi

Research output: Contribution to journalReview article

59 Scopus citations

Abstract

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

Original languageEnglish (US)
Pages (from-to)887-900
Number of pages14
JournalCurrent Medicinal Chemistry
Volume11
Issue number7
DOIs
StatePublished - Apr 1 2004

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target'. Together they form a unique fingerprint.

  • Cite this

    Pankiewicz, K. W., Patterson, S. E., Black, P. L., Jayaram, H. N., Risal, D., Goldstein, B. M., Stuyver, L. J., & Schinazi, R. F. (2004). Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target. Current Medicinal Chemistry, 11(7), 887-900. https://doi.org/10.2174/0929867043455648